Show simple item record

dc.contributor.authorMenéndez-Gutiérrez, María Piedad 
dc.contributor.authorRoszer, Tamas 
dc.contributor.authorRicote, Mercedes 
dc.date.accessioned2020-05-05T08:06:40Z
dc.date.available2020-05-05T08:06:40Z
dc.date.issued2012-03
dc.identifier.citationCurr Top Med Chem. 2012; 12(6):548-84es_ES
dc.identifier.issn1568-0266es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9876
dc.description.abstractPeroxisome proliferator-activated receptors (PPARs) are ligand dependent transcription factors. The three mammalian PPARs are key regulators of fatty acid and lipoprotein metabolism, glucose homeostasis, cellular proliferation/ differentiation and the immune response. PPARs are therefore important targets in the treatment of metabolic disorders such as insulin resistance and type 2 diabetes mellitus, and are also of interest in relation to chronic inflammatory diseases such as atherosclerosis, arthritis, chronic pulmonary inflammation, pancreatitis, inflammatory bowel disease, and psoriasis. Recent advances have attributed novel functions to PPARs in blood pressure regulation, neuroinflammation, nerve-cell protection, inflammatory pain reduction, and the hypothalamic control of metabolism. The abundant pleiotropic actions of PPARs suggest that PPAR agonists have enormous therapeutic potential. However, current PPAR-based therapies often have undesired side effects due to the concomitant activation of PPARs in non-target cells. There is therefore growing interest in the development of cell-specific PPAR agonists and improvement of the clinical use of PPAR ligands. This review gives an overview of PPAR functions and discusses the current and potential medical implications of PPAR ligands in various pathologies, ranging from metabolic disorders to cardiovascular disease, chronic inflammation, neurodegenerative disorders and cancer.es_ES
dc.description.sponsorshipThe work performed in the authors’ laboratory was funded by awards from the Spanish Ministry of Science and Innovation (SAF2009 07466) and the Fundación Genoma España, Marató TV3 to M. Ricote, and a “People” Marie Curie Intra European Fellowship within the 7th European Community Framework Programme to T. Rőszer. The CNIC is supported by the S Spanish Ministry of Health and Consumer Affairs and the Pro-CNIC Foundationes_ES
dc.language.isoenges_ES
dc.publisherBentham Science Publishers es_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAnimals es_ES
dc.subject.meshHumans es_ES
dc.subject.meshLigands es_ES
dc.subject.meshPeroxisome Proliferator-Activated Receptors es_ES
dc.subject.meshMolecular Targeted Therapy es_ES
dc.titleBiology and therapeutic applications of peroxisome proliferator- activated receptorses_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID22242855es_ES
dc.format.volume12es_ES
dc.format.number6es_ES
dc.format.page548-84es_ES
dc.identifier.doi10.2174/156802612799436669es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderFundación Genoma España
dc.contributor.funderFundació La Marató
dc.contributor.funderMinisterio de Sanidad y Consumo (España)
dc.contributor.funderFundación ProCNIC
dc.description.peerreviewedes_ES
dc.identifier.e-issn1873-4294es_ES
dc.relation.publisherversionhttps://doi.org/10.2174/156802612799436669es_ES
dc.identifier.journalCurrent topics in medicinal chemistryes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Señalización de los Receptores Nucleareses_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional